Immunohistochemical expression pattern of MMR protein can specifically identify patients with colorectal cancer microsatellite instability

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6283-6291

  Amira, Arfaoui Toumi ^a,c   Mouna, Trabelsi ^a   Ahlem, Blel ^a   Raoudha, Aloui ^a   Majid, Ben Hmida ^b   Amel, Hamza ^a   Rachida, Zermani ^a   Nadia, Kourdaa ^a  

^a CHARLES NICOLLE HOSPITAL   (Tunisia)

^b UNIVERSITY OF TUNIS   (Tunisia)

^c NONE   (Tunisia)

Author keywords

Colorectal carcinomas; Immunohistochemistry; Microsatellite instability; MMR genes; MSI phenotype; MSI status

Indexed keywords

MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE PRODUCT; GENETIC ASSOCIATION; GENETIC RISK; GERMLINE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUNISIA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; NUCLEAR PROTEINS; PHENOTYPE; TUNISIA;

EID: 84905015884     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1831-2     Document Type: Article

References (39)

1. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Rüschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997;57:4749-56. (Pubitemid 27468981)
2. Wheeler JMD. Epigenetics, mismatch repair genes and colorectal cancer. Ann R Coll Surg Engl. 2005;87:15-20. (Pubitemid 40104226)
3. Kin C, Kidess E, Poultsides GA, Visser BC, Jeffrey SS. Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. Expert Rev Mol Diagn. 2013;6:581-99.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63(1):11-30.
5. O'Regan T, Chau K, Tatton M, Smith T, Parry S, Bissett I. Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel. N Z Med J. 2013;126:70-7.
6. Garre P, Martín L, Bando I, Tosar A, Llovet P, Sanz J, et al. Cancer risk and overall survival in mismatch repair proficient hereditary nonpolyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer. Fam Cancer. 2013;13(1):109-19.
7. Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. 2013.
8. Kheirelseid EA, Miller N, Chang KH, Curran C, Hennessey E, Sheehan M, et al. Mismatch repair protein expression in colorectal cancer. J Gastrointest Oncol. 2013;4(4):397-408.
9. Win AK, Macinnis RJ, Dowty JG, Jenkins MA. Criteria and prediction models for mismatch repair gene mutations: a review. J Med Genet. 2013;50(12):785-93.
10. Oliveira C, Seruca R, Seixas M, Sobrinho-Simoes M. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. Am J Pathol. 1998;153:1211-9.
11. Boland GM, Chang GJ, Haynes AB, Chiang YJ, Chagpar R, Xing Y, et al. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer. 2013;119(8):1593-601.
12. Hartman DJ, Brand RE, Hu H, Bahary N, Dudley B, Chiosea SI, et al. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectumand late-onset presentation supports a universal screening approach. Hum Pathol. 2013;44(11):2518-28.
13. Kloor M. Pathogenesis of microsatellite-unstable colorectal cancer. Evaluation of new diagnostic and therapeutic options. Pathologe. 2013;34 Suppl 2:277-81.
14. Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer. 2004;4:153-8. (Pubitemid 38198743)
15. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology. 2002;123:1804-11. (Pubitemid 35408304)
16. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
17. Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer. 2013;133(1):130-41.
18. De la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28(20):3380-7.
19. Michael-Robinson JM, Reid LE, Purdie DM, Biemer-Hüttmann AE, Walsh MD, Pandeya N, et al. Proliferation, apoptosis, and survival in high-level microsatellite instability sporadic colorectal cancer. Clin Cancer Res. 2001;7(8):2347-56. (Pubitemid 32751635)
20. Esemuede I, Forslund A, Khan SA, Qin LX, Gimbel MI, Nash GM, et al. Improved testing for microsatellite instability in colorectal cancer using a simplified 3-marker assay. Ann Surg Oncol. 2010;17(12):3370-8.
21. Edmonston TB, Cuesta KH, Burkholder S, Barusevicius A, Rose D, Kovatich AJ, et al. Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic andmolecular entity with respect to prognostic markers. Hum Pathol. 2000;31(12):1506-14. (Pubitemid 32047002)
22. Niv Y. Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil. Isr Med Assoc J. 2005;7(8):520-4. (Pubitemid 41102876)
23. Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in pat ients with colorectal cancer receiving chemotherapy. Gastroenterology. 2000;119(4):921-8.
24. Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer. 2001;1(2):104-9.
25. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, Goossens M, Ouchene H, Hendriks-Cornelissen SJ, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2013 [Epub ahead of print].
26. Aissi S, Buisine MP, Zerimech F, Kourda N, Moussa A, Manai M, et al. Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia. World J Gastroenterol. 2013;19(32): 5286-94.
27. Marra G, Jiricny J. DNA mismatch repair and colon cancer. Adv Exp Med Biol. 2005;570:85-123. (Pubitemid 47413187)
28. Rigau V, Nicole Sebbagh BS, Sylviane O, Francois P, Najat M, Yann P, et al. Microsatellite instability in colorectal carcinoma: the comparison of immunohistochemistry and molecular biology suggests a role for hMLH6 immunostaining. Arch Pathol Lab Med. 2003;127: 694-700. (Pubitemid 36617287)
29. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 2012;104(21):1635-46.
30. Kang BW, Kim JG, Lee SJ, Chae YS, Moon JH, Sohn SK, et al. Clinical significance of microsatellite instability for stage II or III colorectal cancer following adjuvant therapy with doxifluridine. Med Oncol. 2011;28(1):214-8.
31. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 1997;57: 808-11. (Pubitemid 27097998)
32. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Mod Pathol. 2002;15(7):741-9.
33. Kria Ben Mahmoud L, Arfaoui A, Khiari M, Chaar I, Lounis A, Sammoud S, et al. Evaluation of microsatellite instability, MLH1 expression and hMLH1 promoter hypermethylation in colorectal carcinomas among Tunisians patients. Tunis Med. 2012;90(8-9): 646-53.
34. Malhotra P, Anwar M, Kochhar R, Ahmad S, Vaiphei K, Mahmood S. Promoter methylation and immunohistochemical expression of hMLH1 and hMSH2 in sporadic colorectal cancer: a study from India. Tumour Biol. 2013. doi:10.1007/s13277- 013-1487-3.
35. Lawes DA, Pearson T, SenGupta S, Boulos PB. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers. Br J Cancer. 2005;93:472-7. (Pubitemid 43080023)
36. Lech G, Slotwinski R, Krasnodebski IW. The role of tumor markers and biomarkers in colorectal cancer. Neoplasma. 2014;61(1):1-8.
37. Patil DT, Bronner MP, Portier BP, Fraser CR, Plesec TP, Liu X. A five-marker panel in a multiplex PCR accurately detects microsatellite instability-high colorectal tumors without control DNA. Diagn Mol Pathol. 2012;21(3):127-33.
38. Serrano M, Lage P, Belga S, Filipe B, Francisco I, Rodrigues P, et al. Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome. Fam Cancer. 2012;11(4): 571-8.
39. Lanza G, Gafà R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol. 2002;15(7):741-9. (Pubitemid 34787310)